Skip to main content

NCT00650806 - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-28431754 in Nondiabetic Overweight and Obese Subjects

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-28431754 in Nondiabetic Overweight and Obese Subjects


CSR Summary

Not Yet Available


Data Specification

Available upon data request approval


Annotated CRF

Available upon data request approval

Product Info

Generic Name
Canagliflozin
Product Name
INVOKANA®
Therapeutic Area
Nutritional and Metabolic Diseases
Enrollment
376
% Female
86.0%
% White
83.0%
Product Class
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor
Sponsor Protocol Number
28431754OBE2001
Data Partner
Johnson & Johnson
Condition Studied
Obesity
Mean/Median Age (Years)
44.8

Supporting Documentation

Collected Datasets
Data Definition Specification
Annotated Case Report Form
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
2

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.